Chara Stavraka is an NIHR Academic Clinical fellow and Specialist Registrar in Medical Oncology at Guy's and St Thomas' NHS Foundation Trust.
She was awarded a competitive 3-year Imperial/CRUK clinical PhD fellowship to investigate the role of the RNA binding protein LARP1 as a post-trascriptional regulator of cisplatin resistance in ovarian cancer.
She graduated from the Medical School of the Aristotle University of Thessaloniki in 2009 and was awarded an MRes in Translational Medicine by Imperial College in 2010. She then worked as a Clinical Research Fellow in the early phase Clinical trials Unit of Imperial College gaining extensive experience in Phase I Oncology studies of molecularly targeted drugs. Having successfully completed her Core Medical Training she became a Member of the Royal College of Physicians (MRCP) in 2014.
Chara has presented her research in several highly esteemed international Oncology meetings and published in peer reviewed journals. Her efforts have been recognised with the prestigious Scholar in Training award by the American Association for Cancer Research in 2016.
She has been actively involved in undergraduate and postgraduate teaching both in the clinical and academic field and her contribution has been elected as an Associate Fellow of the Higher Education Academy.
et al., 2022, Clinical and Translational Significance of Basophils in Patients with Cancer, Cells, Vol:11
et al., 2021, Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies, Clinical and Experimental Immunology, ISSN:0009-9104
et al., 2021, Insights from IgE immune surveillance in allergy and cancer for anti-tumour IgE treatments, Cancers (basel), Vol:13, ISSN:2072-6694
et al., 2021, The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer, Annals of Translational Medicine, Vol:9, ISSN:2305-5839, Pages:1-11
et al., 2021, Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors, 44th Congress of the European-Society-for-Medical-Oncology (ESMO), CIG MEDIA GROUP, LP, Pages:342-349, ISSN:1533-0028